Sign in
Active, not recruitingPhase 2

Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

Key facts

Who runs it
Suzhou Alphamab Co., Ltd.
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
Phase
Phase 2
People taking part
241 people enrolled
Started
20 Dec 2023
Ended
15 Apr 2026
Type of study
Interventional, 4 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Enoxaparin
  • KN060 Low
  • KN060 Middle
  • KN060 Hight
Record updated
17 September 2025

Who can take part

Age
18 years to 75 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 7 criteriaShow less

Who can take part

  • Male or female, aged between 18 and 75 years old (including the cut-off value)
  • undergoing unilateral Total Knee Arthroplasty (TKA)
  • Voluntarily participate in the study and sign a written informed consent

Who cannot take part

  • Acute myocardial infarction or ischemic stroke occurred within 6 months before screening
  • There is a high risk of bleeding or abnormal bleeding related indicators:
  • Evidence of venous thrombosis, such as the presence of related symptoms or auxiliary tests indicating thrombosis; Or have a history of venous embolic disease
  • Presence of malignant tumors or history of malignant tumors

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

The 4 groups in the trial

  • EnoxaparinExisting treatment, for comparison

    Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received enoxaparin for at least 10 days post-surgery.

  • KN060 Low (post-surgery)Treatment being tested

    Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 low dose once post-surgery.

    Treatment: KN060 Low

  • KN060 Middle (post-surgery)Treatment being tested

    Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 middle dose once post-surgery.

    Treatment: KN060 Middle

  • KN060 Hight (post-surgery)Treatment being tested

    Adult patients who underwent Total Knee Arthroplasty (TKA) surgery and received KN060 hight dose once post-surgery.

    Treatment: KN060 Hight

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
An Open, Randomized, Active-comparator-controlled, Multicenter Study to Assess the Efficacy and Safety of Different Doses of KN060 for the Prevention of Venous Thromboembolism in Patients Undergoing Unilateral Total Knee Arthroplasty.
Record updated
17 September 2025